← board
NMAD
distress 8/10 · high distress / dilution risk$4.76-5%today-41% from 52w high
Lead: advanced soft tissue sarcoma
Revenue
pre-revenue
Liquidity
$3M
Runway
0.8 yrs
Shares 1y
+172%
Price & events
+42.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.6%
1D
-11.7%
1W
-34.8%
1M
+19.6%
3M
+42.9%
6M
+14.7%
1Y
+103.4%
2Y
-83.0%
5Y
-85.2%
All
Overview
- Market Cap
- $58.94M
- Volume
- 41.07K
- 52 Week Range
- $2.44 – $8.04
- Total Shares
- 12.38M
- Short %
- 2.24%
- RVOL
- 0.08x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- early in 2025readoutPhase 1LB-100 · First phase data from LB-100 plus standard chemotherapy in advanced soft tissue sarcomaSEC 8-K
- 2024-08-26partnershipLB-100 · Collaboration with Netherlands Cancer Institute and Roche for clinical trial in colorectal cancerSEC 8-K
- August 26, 2024trial initiationsecondaryLB-100 · First patient dosed in clinical trial for LB-100 in collaboration with NKI and RocheSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — advanced soft tissue sarcoma
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.